CPRX
Price
$14.89
Change
+$0.21 (+1.43%)
Updated
Apr 26, 6:59 PM EST
10 days until earnings call
HALO
Price
$38.57
Change
+$0.11 (+0.29%)
Updated
Apr 26, 6:59 PM EST
10 days until earnings call
Ad is loading...

CPRX vs HALO ᐉ Comparison: Which is Better to Invest?

Header iconCPRX vs HALO Comparison
Open Charts CPRX vs HALOBanner chart's image
Catalyst Pharmaceuticals
Price$14.89
Change+$0.21 (+1.43%)
Volume$458.57K
CapitalizationN/A
Halozyme Therapeutics
Price$38.57
Change+$0.11 (+0.29%)
Volume$299.5K
CapitalizationN/A
View a ticker or compare two or three
CPRX vs HALO Comparison Chart

Loading...

CPRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
HALODaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CPRX vs. HALO commentary
Apr 28, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CPRX is a StrongSell and HALO is a Hold.

COMPARISON
Comparison
Apr 28, 2024
Stock price -- (CPRX: $14.89 vs. HALO: $38.57)
Brand notoriety: CPRX and HALO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CPRX: 56% vs. HALO: 55%
Market capitalization -- CPRX: $1.76B vs. HALO: $4.9B
CPRX [@Biotechnology] is valued at $1.76B. HALO’s [@Biotechnology] market capitalization is $4.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $568.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.54B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CPRX’s FA Score shows that 1 FA rating(s) are green whileHALO’s FA Score has 1 green FA rating(s).

  • CPRX’s FA Score: 1 green, 4 red.
  • HALO’s FA Score: 1 green, 4 red.
According to our system of comparison, CPRX is a better buy in the long-term than HALO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CPRX’s TA Score shows that 2 TA indicator(s) are bullish while HALO’s TA Score has 4 bullish TA indicator(s).

  • CPRX’s TA Score: 2 bullish, 6 bearish.
  • HALO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, HALO is a better buy in the short-term than CPRX.

Price Growth

CPRX (@Biotechnology) experienced а -1.59% price change this week, while HALO (@Biotechnology) price change was -0.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.69%. For the same industry, the average monthly price growth was -8.16%, and the average quarterly price growth was +1262.42%.

Reported Earning Dates

CPRX is expected to report earnings on Aug 07, 2024.

HALO is expected to report earnings on Aug 06, 2024.

Industries' Descriptions

@Biotechnology (+1.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CPRX with price predictions.
OPEN
A.I.dvisor published
a Summary for HALO with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
HALO($4.9B) has a higher market cap than CPRX($1.76B). CPRX has higher P/E ratio than HALO: CPRX (23.63) vs HALO (18.37). HALO YTD gains are higher at: 4.356 vs. CPRX (-11.422).
CPRXHALOCPRX / HALO
Capitalization1.76B4.9B36%
EBITDAN/AN/A-
Gain YTD-11.4224.356-262%
P/E Ratio23.6318.37129%
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
CPRX vs HALO: Fundamental Ratings
CPRX
HALO
OUTLOOK RATING
1..100
6250
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
2939
SMR RATING
1..100
4711
PRICE GROWTH RATING
1..100
5548
P/E GROWTH RATING
1..100
4275
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CPRX's Valuation (71) in the Pharmaceuticals Other industry is in the same range as HALO (88) in the Biotechnology industry. This means that CPRX’s stock grew similarly to HALO’s over the last 12 months.

CPRX's Profit vs Risk Rating (29) in the Pharmaceuticals Other industry is in the same range as HALO (39) in the Biotechnology industry. This means that CPRX’s stock grew similarly to HALO’s over the last 12 months.

HALO's SMR Rating (11) in the Biotechnology industry is somewhat better than the same rating for CPRX (47) in the Pharmaceuticals Other industry. This means that HALO’s stock grew somewhat faster than CPRX’s over the last 12 months.

HALO's Price Growth Rating (48) in the Biotechnology industry is in the same range as CPRX (55) in the Pharmaceuticals Other industry. This means that HALO’s stock grew similarly to CPRX’s over the last 12 months.

CPRX's P/E Growth Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for HALO (75) in the Biotechnology industry. This means that CPRX’s stock grew somewhat faster than HALO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CPRXHALO
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
67%
MACD
ODDS (%)
Bearish Trend 4 days ago
83%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 4 days ago
72%
Declines
ODDS (%)
Bearish Trend 5 days ago
70%
Bearish Trend 10 days ago
68%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
69%
Aroon
ODDS (%)
Bearish Trend 2 days ago
62%
Bearish Trend 2 days ago
63%
View a ticker or compare two or three
Ad is loading...
CPRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
HALODaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RSST23.630.64
+2.78%
Return Stacked® US Stocks & Mgd Futs ETF
NUMG42.010.33
+0.79%
Nuveen ESG Mid-Cap Growth ETF
CDEI62.940.25
+0.40%
Calvert US Large-Cp Div, Eq AndIncETF
CGCP21.980.06
+0.27%
Capital Group Core Plus Income ETF
BBIB94.870.12
+0.13%
JPMorgan BetaBuilders U.S.TrsBd3-10YrETF

CPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CPRX has been loosely correlated with MNKD. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CPRX jumps, then MNKD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPRX
1D Price
Change %
CPRX100%
+1.43%
MNKD - CPRX
40%
Loosely correlated
+1.20%
VCEL - CPRX
38%
Loosely correlated
+1.32%
ABOS - CPRX
38%
Loosely correlated
-0.63%
XNCR - CPRX
37%
Loosely correlated
+3.90%
RNA - CPRX
37%
Loosely correlated
+2.22%
More